F S&P 500
5,009.75 -39.25 (-0.78%) F Dow Jones
37,724.00 -283.00 (-0.74%) F Nasdaq
17,386.50 -160.75 (-0.92%) E-mini Russell 2000 Index Futur
1,937.40 -20.70 (-1.06%) Petróleo
84.49 +1.76 (+2.13%) Oro
2,402.90 +4.90 (+0.20%)
Ardelyx, Inc. (ARDX)
Fuera de horario:
Ardelyx, Inc.
400 Fifth Avenue
Suite 210
Waltham, MA 02451
United States
510 745 1700
https://www.ardelyx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 267
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Michael G. Raab | President, CEO & Director | 1.28M | N/D | 1965 |
| Ms. Susan Rodriguez | Chief Commercial Officer | 760.77k | N/D | 1964 |
| Dr. Laura A. Williams M.D., M.P.H. | Chief Medical Officer | 873.8k | N/D | 1964 |
| Mr. Justin A. Renz CPA, MBA | Chief Financial & Operations Officer and Treasurer | 623.7k | N/D | 1972 |
| Mr. Robert Felsch | Senior VP of Finance & Chief Accounting Officer | N/D | N/D | N/D |
| Ms. Elizabeth A. Grammer Esq. | Chief Legal & Administrative Officer and Secretary | 623.7k | N/D | 1964 |
| Ms. Caitlin Lowie | Vice President of Corporate Communications & Investor Relations | N/D | N/D | N/D |
| Mr. Mike Kelliher | Executive Vice President of Corporate Development & Strategy | N/D | N/D | N/D |
| Ms. Charon Spencer Sr. | Chief Human Resources Officer | N/D | N/D | N/D |
| Mr. David P. Rosenbaum | Chief Development Officer | 645.4k | N/D | 1961 |
Descripción
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de Ardelyx, Inc. a partir del 1 de abril de 2024 es 8. Las puntuaciones principales son Auditoría: 9; Junta: 7; Derechos del accionista: 8; Compensación: 9.
